HER2 Mutation-Related Tumors research hub

A Phase 1/1b Study of IAM1363 in HER2 Cancers

This study is testing a new medicine called IAM1363 for advanced cancers with a specific change called HER2. It aims to find a safe and effective dose, including for breast, lung, and stomach cancers that have spread to the brain.

SAFIR 03_A ctDNA screening program in patients with HR+, HER2- metastatic breast cancer for detection of high-risk relapse patients on any CDK4/6 inhibitor and a randomised phase II study comparing alpelisib combined with fulvestrant to ribociclib combined with fulvestrant, in patients with persistent targetable PIK3CA mutations.